Stryker Corporation reported a strong fourth quarter for 2025, with adjusted earnings per share of $4.47, exceeding the Zacks Consensus Estimate of $4.40. The company achieved total revenues of $7.17 billion and a full-year revenue of $25.1 billion, reflecting an 11.2% growth year-over-year. Despite solid performance, Stryker received a downgrade from TD Cowen to a 'Hold' with a price target of $387, although it expects robust sales growth of 8-9.5% for 2026 and adjusted EPS between $14.90 and $15.10.
“Stryker Corporation · reported fourth-quarter 2025 adjusted earnings per share (EPS) · adjusted EPS · $4.47”
“Stryker Corporation · beat the Zacks Consensus Estimate · Zacks Consensus Estimate of adjusted EPS · $4.40”
“Stryker Corporation · GAAP EPS · GAAP EPS · $2.22”
“Stryker Corporation · full-year adjusted EPS gained · adjusted EPS · 11.8%”
“Stryker Corporation · full-year sales totaled · full-year sales · $25.1 billion”
“Stryker Corporation · spinal implants business was sold to · Viscogliosi Brothers, LLC · April 2025”
“Stryker Corporation · reported sales for MedSurg and Neurotechnology · sales · $4.6 billion”
“Stryker Corporation · adjusted gross profit totaled · adjusted gross profit · $4.68 billion”
“Stryker Corporation · cash and cash equivalents at the end of the fourth quarter · cash and cash equivalents · $4.01 billion”
“Stryker Corporation · issued guidance for total revenues to grow in 2026 · total revenues growth · 8-9.5%”
“Stryker Corporation · expects EPS for full-year 2026 to be · EPS range · $14.90 to $15.10”
“Stryker Corporation · global installed base of Mako systems exceeds · Mako systems · 3,000 systems”
